
ProBio and AbTis partner on next-generation antibody-drug conjugate
CRDMO ProBio and South Korean biotechnology company AbTis have agreed an exclusive global licensing agreement for the development of antibody-drug conjugates (ADCs). AbTis will receive exclusive global rights to develop and commercialise a discovery-stage therapeutic antibody asset generated through ProBio’s biologics discovery and development capabilities against an… Read More

